Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations

Summary

This study compared the efficacy of indacaterol versus placebo in COPD patients classified as GOLD 2014 Patient Group B. This was a 2-arm parallel group study that recruited COPD patients classified by GOLD Patient Gorup B. On successful completion of run-in period, patients were randomized in the ratio 1:1 to receive prn salbutamol plus: 1. Indacaterol 150ug or 2. Placebo for indacaterol all once daily (od) for 26 weeks. The primary objective (trough FEV1) was assessed after 12 weeks.

Timeline

Start

2015-04-28

Primary completion

2016-04-19

Completion

2016-04-19

Drugs

Indications